Advertisement

 

 

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom’s Macroglobulinemia.

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom’s Macroglobulinemia.
Author Information (click to view)

Chin CK, Leslie C, Grove CS, Van Vliet C, Cheah CY,


Chin CK, Leslie C, Grove CS, Van Vliet C, Cheah CY, (click to view)

Chin CK, Leslie C, Grove CS, Van Vliet C, Cheah CY,

Advertisement

International journal of molecular sciences 2017 09 2218(10) pii E2038
Abstract

The application of molecular genomics and our understanding of its clinical implications in the diagnosis, prognostication and treatment of lymphoproliferative disorders has rapidly evolved over the past few years. Of particular importance are indolent B-cell malignancies where tumour cell survival and proliferation are commonly driven by mutations involving the B-cell receptor and downstream signalling pathways. In addition, the increasing number of novel therapies and targeted agents have provided clinicians with new therapeutic options with the aim of exploiting such mutations. In this case report, we highlight one such success story involving the diagnostic impact of the MYD88(L265P) mutation in Waldenstrom’s macroglobulinemia (WM), its prognostic implications and effect on choice of therapy in the era of novel therapies.

Submit a Comment

Your email address will not be published. Required fields are marked *

six − 5 =

[ HIDE/SHOW ]